| アブストラクト | Effectors from the immune system can modulate the course and possibly the early development of gliomas. We, therefore, hypothesized that autoimmune diseases associated with increased immune-surveillance may also modulate the risk of human glioma. To test this hypothesis, we used data from the well-validated Clinical Practice Research Datalink (CPRD) GOLD from the UK to analyze the association of immune-related disorders or use of immunosuppressive drugs and the risk of glioma. We identified 3112 incident glioma cases diagnosed between 1995 and 2017. We randomly selected up to 10 controls, matching them to glioma cases on age, sex, index date, general practice, and number of years of active history in the database prior to the index date. We performed conditional logistic regression analyses to estimate Odds Ratios (ORs) of glioma among those exposed to allergies, autoimmune diseases, and immunosuppressive drugs. Overall, we found no materially altered association between a history of any autoimmune disease (OR 0.98, 95% CI 0.86-1.11), allergy (OR 0.97, 95% CI 0.89-1.05), or use of immunosuppressive drugs and the risk of glioma. However, subgroup analyses among younger patients found a statistically significant increased risk of glioma in patients with a history of inflammatory bowel disease (IBD) (OR 2.59, 95% CI 1.31-5.12). There was also an inverse association between asthma and risk of glioma in patients with longer survival (OR 0.73, 95% CI 0.58-0.91) and between long-term duration diabetes and risk of glioma (OR 0.71, 95% CI 0.53-0.96). |
|---|
| ジャーナル名 | Cancer medicine |
|---|
| Pubmed追加日 | 2019/12/11 |
|---|
| 投稿者 | Anssar, Tareq M; Leitzmann, Michael F; Linker, Ralf A; Meier, Christoph; Becker, Claudia; Jick, Susan; Sahm, Katharina; Platten, Michael; Hau, Peter; Seliger, Corinna |
|---|
| 組織名 | Wilhelm Sander-NeuroOncology Unit and Department of Neurology, Regensburg;University Hospital, Regensburg, Germany.;Institute of Epidemiology and Preventive Medicine, Regensburg University;Hospital, Regensburg, Germany.;Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,;Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.;Boston Collaborative Drug Surveillance Program, Lexington, United States.;Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.;Boston University School of Public Health, Lexington, United States.;Department of Neurology, Mannheim Medical Center, University of Heidelberg,;Mannheim, Germany.;DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research;Center, Heidelberg, Germany.;Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31821741/ |
|---|
